Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totalling 228,000 shares, a decline of 6.2% from the August 15th total of 243,100 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average daily volume of 163,500 shares, the days-to-cover ratio is currently 1.4 days.

Bolt Biotherapeutics Trading Up 2.3 %

BOLT traded up $0.01 during trading on Wednesday, reaching $0.64. The company had a trading volume of 15,264 shares, compared to its average volume of 172,875. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.28 and a current ratio of 4.28. Bolt Biotherapeutics has a 12-month low of $0.61 and a 12-month high of $1.56. The firm’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.90. The company has a market cap of $24.58 million, a price-to-earnings ratio of -0.38 and a beta of 0.93.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative net margin of 592.57% and a negative return on equity of 61.40%. The business had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.19 million. Equities research analysts anticipate that Bolt Biotherapeutics will post -1.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Thursday, August 15th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and an average target price of $3.50.

Hedge Funds Weigh In On Bolt Biotherapeutics

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. bought a new stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned approximately 0.09% of Bolt Biotherapeutics at the end of the most recent reporting period. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.